The region’s robust fundraising in the life sciences sector continues as two Philadelphia-based biotechnology companies recently announced initial public offerings.
Century Therapeutics, Inc. announced the closing of its initial public offering valued at $242.7 million on June 22. The company is utilizing a comprehensive cell therapy platform to develop transformative allogeneic cell therapies. Century Therapeutics’ genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. “We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care,” […]